Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250016 | 0.93 | DGAT2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4PDE10A | |
| SCHEMBL17768271 | 0.85 | MTOR (0.39) | PDE10A | |
| SCHEMBL16238790 | 0.81 | ROCK2 (0.37) | CHRNB4CHRNA3PDE10APIM1CYP11B2 | |
| SCHEMBL16754340 | 0.81 | KCNH2 (0.40) | PDE10APIM1KCNH2 | |
| SCHEMBL17778241 | 0.81 | KCNH2 (0.40) | PDE10APIM1KCNH2 | |
| SCHEMBL16238772 | 0.81 | ROCK2 (0.43) | CHRNB4CHRNA3PDE10APIM1CYP11B2 | |
| SCHEMBL16238743 | 0.80 | DGAT2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4PIM1 | |
| SCHEMBL16754650 | 0.79 | USP30 (0.40) | PDE10ACYP11B2USP30 | |
| SCHEMBL17768048 | 0.79 | USP30 (0.40) | PDE10ACYP11B2USP30 | |
| SCHEMBL16239247 | 0.79 | USP30 (0.40) | PDE10ACYP11B2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CHRNB2 4378/4885CHRNB4 4538/4885CHRNA3 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.